The unilateral nigral lesion induces dramatic bilateral modification on rat brain monoamine neurochemistry

Annals of the New York Academy of Sciences

Volumn 1155, Issue , 2009, Pages 316-323

  Pierucci, Massimo ^a   Di Matteo, Vincenzo ^a   Benigno, Arcangelo ^b   Crescimanno, Giuseppe ^b   Esposito, Ennio ^a   Di Giovanni, Giuseppe ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

6 OHDA; Brain stem; Cerebellum; Cortex; High performance liquid chromatography (HPLC); Hippocampus; Monoamines; Parkinson's disease (PD); Striatum

Indexed keywords

BRAIN MONOAMINE; DOPAMINE; OXIDOPAMINE; SEROTONIN;

ANIMAL MODEL; ANIMAL TISSUE; BRAIN CORTEX; BRAIN NUCLEUS; BRAIN STEM; BRAIN STEM INJURY; CEREBELLUM; CONFERENCE PAPER; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; HIPPOCAMPUS; MALE; METABOLITE; NEUROCHEMISTRY; NONHUMAN; RAT; SEROTONIN BRAIN LEVEL; SUBSTANTIA NIGRA;

ANIMALIA; RATTUS;

EID: 61649099593     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2008.03679.x     Document Type: Conference Paper

References (42)

1. Hornykiewicz, O. 1963. The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease. Wien Klin Wochenschr. 75 : 309 312.
2. Esposito, E., V. Di Matteo & G. Di Giovanni. 2007. Death in the substantia nigra: A motor tragedy. Expert Rev. Neurother. 7 : 7677 7697.
3. Di Giovanni, G. 2008. Will it be possible to prevent nigral neurodegeneration? CNS Neurol. Disord. Drug Targets 7 : 28 44.
4. Di Giovanni, G. 2007. The Basal Ganglia Pathophysiology: Recent Advances. Transworld Research Network. Kerala, India.
5. Jellinger, K. 1989. Pathology of Parkinson's disease. In Handbook of Experimental Pharmacology. D.B. Calne, Ed Vol. 8 : 47 112. Springer. Berlin.
6. Scherman, D. et al. 1989. Striatal dopamine deficiency in Parkinson's disease: Role of aging. Ann. Neurol. 26 : 551 557.
7. Di Giovanni, G. et al. 2007. Biochemical and therapeutic effects of antioxidants in the treatment of Parkinson's disease. In The Basal Ganglia Pathophysiology: Recent Advances. G. Di Giovanni, Ed : 253 283 Transworld Research Network. Kerala, India.
8. Di Matteo, V. et al. 2006. 7-nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: An in vivo microdialysis study. Ann. N. Y. Acad. Sci. 1089 : 462 471.
9. Di Matteo, V. et al. 2006. Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: An in vivo microdialysis study. Brain Res. 1095 : 167 177.
10. von Bohlen und Halbach, O., A. Schober & K. Krieglstein. 2004. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog. Neurobiol. 73 : 151 177.
11. Betarbet, R., T.B. Sherer & J.T. Greenamyre. 2002. Animal models of Parkinson's disease. Bioessays 24 : 308 318.
12. Beal, M.F. 2001. Experimental models of Parkinson's disease. Nat. Rev. 2 : 325 332.
13. Schober, A. 2004. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318 : 215 224.
14. Dauer, W. & S. Przedborski. 2003. Parkinson's disease: Mechanisms and models. Neuron 39 : 889 909.
15. Deumens, R., A. Blokland & J. Prickaerts. 2002. Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175 : 303 317.
16. Glinka, Y., M. Gassen & M. B. H. Youdim. 1997. Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm. 50 : 55 66.
17. Hornykiewicz, O. 1998. Biochemical aspects of Parkinson's disease. Neurology 51 : S2 9.
18. Blum, D. et al. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: Contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 : 135 172.
19. Eidelberg, E. et al. 1986. Variability and functional recovery in the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsonism in monkeys. Neuroscience 18 : 817 822.
20. Taylor, J.R. et al. 1997. Severe long-term 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridineinduced Parkinsonism in the Vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 81 : 745 755.
21. Sachs, C. & G. Jonsson. 1975. Mechanisms of action of 6-hydroxydopamine. Biochem. Pharmacol. 24 : 1 8.
22. Luthman, J. et al. 1989. Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: Motor behavior and monoamine alterations at adult stage. Behav. Brain Res. 33 : 267 227.
23. Liang, Q. et al. 2004. 6-hydroxydopamine induces dopaminergic cell degeneration via a caspase-9-mediated apoptotic pathway that is attenuated by caspase-9dn expression. J. Neurosci. Res. 77 : 747 761.
24. Paxinos, G. & C. Watson. 1986. The Rat Brain in Stereotaxic Coordinates. Second Edition. Academic Press. New York, NY.
25. Porter, C.C., J.A. Totaro & C.A. Stone. 1963. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J. Pharmacol. Exp. Ther. 140 : 308 316.
26. Ungerstedt, U. 1976. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome. Pharmacol. Ther. 2 : 37 40.
27. Schwarting, R.K.W. & J.P. Huston. 1996. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 : 275 331.
28. Enz, A., F. Hefti & W. Frick. 1984. Acute administration of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) reduces dopamine and serotonin but accelerates norepinephrine metabolism in the rat brain. Effect of chronic pretreatment with MPTP. Eur. J. Pharmacol. 101 : 37 44.
29. Fornaguera, J. et al. 1994. Behavioural asymmetries and recovery in rats with different degrees of unilateral striatal dopamine depletion. Brain Res. 664 : 178 188.
30. Sherman, T.G. & C.A. Moody. 1995. Alterations in tyrosine hydroxylase expression following partial lesions of the nigrostriatal bundle. Mol. Brain Res. 29 : 285 296.
31. Di Giovanni, G. et al. 2001. m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. Neuroscience 103 : 111 116.
32. Di Matteo, V. et al. 2008. Serotonin modulation of the basal ganglia circuitry: Therapeutic implication for Parkinson's disease and other motor disorders. In Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance. Prog. Brain Res., Vol. 172. G. Di Giovanni, V. Di Matteo & E. Esposito, Eds 423 463. Elsevier. Amsterdam, The Netherlands.
33. Di Giovanni, G. et al. 2006. Serotonin involvement in the basal ganglia pathophysiology: Could the 5-HT2C receptor be a new target for therapeutic strategies? Curr. Med. Chem. 13 : 3069 3081.
34. Hornykiewicz, O. 1989. Ageing and neurotoxins as causative factors in idiopathic Parkinson's disease - A critical analysis of the neurochemical evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry 13 : 319 328.
35. Bezard, E., J.M. Brotchie & C.E. Gross. 2001. Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nat. Rev. Neurosci. 2 : 577 588.
36. Carta, M. et al. 2007. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 130 : 1819 1833.
37. Luthman, J., M. Herrera-Marschitz & E. Lindqvist. 1994. Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: I. Effects on spontaneous and drug-induced rotational behaviour and on post-mortem monoamine levels. Psychopharmacology 116 : 443 50.
38. Molina-Holgado, E. et al. 1993. Changes of amino acid and monoamine levels after neonatal 6-hydroxydopamine denervation in rat basal ganglia, substantia nigra and raphe nuclei. J. Neurosci. Res. 35 : 409 418.
39. Breese, G.R. et al. 1984. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J. Pharmacol. Exp. Ther. 231 : 343 354.
40. Zhou, F.C., S. Bledsoe & J. Murphy. 1991. Serotonergic sprouting is induced by dopamine-lesion in substantia nigra of adult rat brain. Brain Res. 556 : 108 116.
41. Hahn, Z., Z. Karadi & L. Lenard. 1981. Striatal dopamine levels after unilateral lesions of the substantia nigra: Evidence for a contralateral decrease. Acta Physiol. Acad. Sci. Hung. 57 : 249 253.
42. Miller, K.M. et al. 2007. Depression symptoms in movement disorders: Comparing Parkinson's disease, dystonia, and essential tremor. Mov. Disord. 22 : 666 672.